Diseases

uniQure N.V. has received an important regulatory milestone in its effort to develop a gene therapy for Huntington’s disease after the US Food and Drug Administration (FDA) accepted its…
Read More...

Circular Genomics and PharmatrophiX have announced a strategic collaboration to use blood-based circular RNA (circRNA) biomarkers to support the development of new treatments for…
Read More...

Estuary Biotherapeutics has launched with $103 million in committed financing to develop targeted gene therapies for autosomal dominant polycystic kidney disease (ADPKD), a genetic…
Read More...

Clinical-stage biotechnology company Tenaya Therapeutics has announced a new research collaboration with RNA interference specialist Alnylam Pharmaceuticals aimed at identifying novel…
Read More...

AstraZeneca has strengthened its weight management and metabolic disease pipeline through a new strategic collaboration with CSPC Pharmaceuticals, targeting the development of multiple…
Read More...

China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

InterAx Biotech Ltd and Alveus Therapeutics Inc. have entered into a strategic research collaboration and licensing agreement aimed at developing a differentiated small-molecule therapy…
Read More...

Sandoz has signed a non-binding term sheet with Evotec SE to potentially acquire Just–Evotec Biologics EU SAS, including its state-of-the-art J.POD biologics development and…
Read More...

Since announcing their partnership in April 2025, AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care across Ghana, from early diagnosis to…
Read More...

A new potential treatment for generalised myasthenia gravis (gMG), a rare and debilitating autoimmune neuromuscular disease, has shown promising results in a large international…
Read More...

Porton Advanced Solutions, a global leader in cell and gene therapy contract development and manufacturing (CDMO), has signed a Memorandum of Understanding (MOU) with EVA Pharma, a…
Read More...

Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to update the label of Ozempic…
Read More...

RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) as a pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1.…
Read More...

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying…
Read More...

Ferrer has announced that its investigational therapy FNP-223, developed to treat progressive supranuclear palsy (PSP), has received Fast Track designation from the U.S. Food and Drug…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of…
Read More...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease,…
Read More...

REVEAL GENOMICS and Ona Therapeutics announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the…
Read More...

Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application…
Read More...